Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol (2015) 2.17

How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers. J Clin Oncol (2014) 1.99

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature (2016) 1.95

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLoS One (2015) 1.38

Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. BMC Cancer (2015) 0.87

Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl) (2014) 0.86

Treatment of early-stage HER2+ breast cancer-an evolving field. Ecancermedicalscience (2015) 0.79

Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. J Clin Oncol (2016) 0.79

Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma. Ann Surg Treat Res (2015) 0.78

Toward precision medicine of breast cancer. Theor Biol Med Model (2016) 0.77

Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. Oncotarget (2016) 0.77

Infracentimetric HER-2 positive breast tumours-review of the literature. Ecancermedicalscience (2015) 0.75

[Is the waiver of chemotherapy for small, node-negative breast cancer justified? ]. Strahlenther Onkol (2015) 0.75

Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer. J Nat Prod (2016) 0.75

Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. Breast Cancer Res Treat (2016) 0.75

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer (2015) 0.75

SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol (2015) 0.75

Recurrence risk perception and quality of life following treatment of breast cancer. Breast Cancer Res Treat (2016) 0.75

The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence. Breast Cancer Res Treat (2016) 0.75

Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer. J Cancer (2017) 0.75

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Geburtshilfe Frauenheilkd (2017) 0.75

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25

Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med (2005) 16.70

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25

Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52

Can comorbidity be measured by questionnaire rather than medical record review? Med Care (1996) 10.53

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol (2007) 6.11

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 4.57

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05

Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst (2006) 4.01

Breast cancer treatment and natural history: new insights from results of screening. Lancet (1992) 3.77

Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol (2014) 3.08

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol (2009) 2.98

Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol (2006) 2.93

A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol (1989) 2.71

Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol (2008) 2.38

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer (2010) 2.25

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst (2012) 2.21

Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol (2012) 2.18

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol (2013) 2.12

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst (2001) 2.12

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66

Paclitaxel-induced neuropathy. Ann Oncol (1995) 1.65

Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood (2013) 1.64

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer (2011) 1.56

Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network. Oncology (Williston Park) (1999) 1.51

Outcomes assessment in the NCCN. Oncology (Williston Park) (1997) 1.45

Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol (2007) 1.44

NCCN outcomes research database: data collection via the Internet. Oncology (Williston Park) (2000) 1.26

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res (2012) 1.26

The effect of tissue fixation and processing on breast cancer size. Hum Pathol (2005) 1.24

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat (2010) 1.05

Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients. Ann Surg Oncol (2007) 1.04

Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol (2014) 1.02

Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist (2010) 0.99

The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States. Breast Cancer Res Treat (2004) 0.97

Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network. Int J Radiat Oncol Biol Phys (2008) 0.95

Insights into breast cancer screening of younger women. Evidence from the 14-year follow-up of the Breast Cancer Detection Demonstration Project. Cancer (1993) 0.87

Does breast cancer tumor size really matter that much? Breast (2012) 0.85

Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ? World J Surg (2012) 0.82